Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business
In short
Mankind Pharma said its Q2 profit after tax rose 37.7%, and revenue increased 17.3% to ₹4,338 crore in Q2 FY27. The company credited strong demand for chronic therapies and growth in Bharat Serums and Vaccines’ speciality portfolio.
This is important for investors because it points to stronger sales and profit, but the report does not give the exact profit number or say what comes next.
What the reporting says
Mankind Pharma reported a 37.7% rise in Q2 PAT, with revenue up 17.3% to ₹4,338 crore in Q2 FY27. The publisher-supplied summary said the growth was supported by strong demand for chronic therapies and gains in Bharat Serums and Vaccines’ speciality portfolio. The immediate takeaway is stronger quarterly performance; the available reporting does not state the exact PAT figure or management outlook.
Why it matters
Mankind Pharma posted stronger quarterly results in Q2 FY27, with revenue rising 17.3% to ₹4,338 crore and PAT up 37.7%, according to the publisher-supplied summary. The cited drivers were chronic therapies and Bharat Serums and Vaccines’ speciality portfolio. The report does not provide the detailed PAT amount, segment breakdown or any guidance, so the full earnings picture remains incomplete.